These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33209190)

  • 1. Structural Approach to Assessing the Innovativeness of New Drugs Finds Accelerating Rate of Innovation.
    Wills TJ; Lipkus AH
    ACS Med Chem Lett; 2020 Nov; 11(11):2114-2119. PubMed ID: 33209190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building a drug development database: challenges in reliable data availability.
    Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
    Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023).
    Schuhmacher A; Gassmann O; Hinder M; Hartl D
    Drug Discov Today; 2024 Sep; 29(9):104128. PubMed ID: 39097219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the research-based pharmaceutical industry in medical progress in the United States.
    Kaitin KI; Bryant NR; Lasagna L
    J Clin Pharmacol; 1993 May; 33(5):412-7. PubMed ID: 8331197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Something new every day: defining innovation and innovativeness in drug therapy.
    Aronson JK
    J Ambul Care Manage; 2008; 31(1):65-8. PubMed ID: 18162799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in specialty pharma business model.
    Ku MS
    J Food Drug Anal; 2015 Dec; 23(4):595-608. PubMed ID: 28911475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of pharmaceuticals: ensuring the future of research and development.
    Serajuddin HK; Serajuddin AT
    J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small biotechs versus large pharma: Who drives first-in-class innovation in oncology?
    Kennedy KH; Gomez K; Thovmasian NJ; Chang DC
    Drug Discov Today; 2023 Feb; 28(2):103456. PubMed ID: 36403884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methuselah's medicine: pharmaceutical innovation and mortality in the United States, 1960-2000.
    Schnittker J; Karandinos G
    Soc Sci Med; 2010 Apr; 70(7):961-8. PubMed ID: 20100632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.